Endocrinology

A decade after bariatric surgery, most teens maintained weight loss and reduced obesity-related conditions such as type 2 diabetes and hypertension.

Richard Pratley, MD, discusses how FLOW mortality data informs the use of semaglutide in patients with chronic kidney disease and type 2 diabetes.

Novo Nordisk will present more detailed data in 2025 and plans to file for an expanded label for Rybelsus for this population.

Brian Hansen, president of CGM at Ascensia Diabetes Care, joins the podcast to discuss the FDA clearance of the Eversense 365 CGM.

The FDA's decision to issue a CRL was announced on October 08, 2024 and cites issues with the timing of the facility inspection.

Time-restricted eating, even without calorie restriction, improved glycemic control and cardiometabolic health in patients with metabolic syndrome.

Our September 2024 monthly recap in endocrinology spotlights regulatory updates, new guidelines, and the latest episodes of Diabetes Dialogue.

A review of 5 highly anticipated FDA decisions expected by year-end, including acoramidis for ATTR-CM, olezarsen for FCS, sotagliflozin for T1D and CKD, and more.

Ascendis Pharma has submitted a sBLA to the FDA for TransCon hGH for the treatment of adults with growth hormone deficiency.

Lack of retinopathy, lower hemoglobin A1c levels, preserved eGFR, microalbuminuria, and lower UPCR were linked to non-DKD.

There were no differences in the treatment effect of ertugliflozin on gout-related outcomes in subgroups based on eric acid quintile or other baseline characteristics.

The FDA has approved the Eversense 365, the world’s first 1-year continuous glucose monitor, with US availability expected in late 2024.

A new study found glucagon-like peptide 1 receptor agonist use was associated with a lower risk of cirrhosis complications for patients with MASLD who did not have cirrhosis.

A follow-up to an earlier episode, this episode features a deep dive into the hosts experience with the Dexcom Stelo sensor.

In this episode, hosts discuss availability of the Abbott Lingo CGM and Embecta’s announcement of FDA clearance for their tubeless patch pump with a 300-unit insulin reservoir.

The endocrinology month in review for August 2024 spotlights 6 pieces of major pipeline news or regulatory announcements as well as multiple episodes of Diabetes Dialogue.

Semaglutide lowers rates of cardiovascular and COVID-19-related deaths in patients with overweight/obesity, offering promising cardio-metabolic and non-cardiovascular benefits.

Rahul Aggarwal, MD, discusses the findings of a SCORED analysis examining sotagliflozin's effects based on diabetes duration.

Michigan Medicine and U-M research finds a bidirectional link between mental health disorders and chronic diabetes complications, urging comprehensive screenings.

In this episode, hosts discuss the implications of Dexcom announcing availability of their Stelo sensor and the FDA clearance of the Omnipod 5 for type 2 diabetes.

FDA expands Omnipod 5 AID system for type 2 diabetes, marking the first AID system approved for both type 1 and type 2 diabetes management.

Dexcom's Stelo, the first OTC glucose sensor, launches in the US on August 26, 2024, offering 15-day wear and HSA/FSA eligibility for as low as $89.99 per 2-pack.

A new study significantly demonstrated semaglutide, but not liraglutide, is associated with suicidal ideation.

This episode focuses on sotagliflozin in type 1 diabetes and other highlights from the ADCES 2024 annual meeting.

In this episode, hosts react to the announced CMS list prices for the first 10 drugs chosen for negotiation as part of the Inflation Reduction Act.

A new analysis suggests HbA1c may be more informative to fatty liver disease severity than BMI, and should be included in screenings.

The first of 2 episodes on ADCES 2024, this episode focuses on sessions and presentations hosts Isaacs and Bellini participated in during the meeting.

A new real-world study suggests tirzepatide provides greater reductions in mortality, cardiovascular risk, and kidney events than GLP-1 receptor agonists in type 2 diabetes.

Palopegteriparatide’s approval was based on positive data from the global Phase 2 PaTH Forward and Phase 3 PaTHway trials.

In this episode, hosts are joined by Muthiah Vaduganathan, MD, MPH, for a discussion around topline data updates from the SUMMIT and FINEARTS-HF trials.